Oxysterol-Bone Targeting Agents for Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and bone fractures are limited by the low bioavailability and side effects of bisphosphonate drugs, and the safety concerns associated with recombinant human bone morphogenetic protein-2 (rhBMP-2) used in spine fusion surgeries, necessitating the development of more effective and safer bone anabolic agents.
Innovation Solution
The synthesis of novel osteogenic oxysterol-bone targeting agent compounds, such as Oxy133-tetracycline derivatives, which selectively target bone tissue to stimulate bone formation through the activation of the Hedgehog signaling pathway, enhancing bone anabolic activity while minimizing systemic toxicity and immunogenic responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bisphosphonate drugs are used to treat osteoporosis, then bone resorption is inhibited, but bioavailability is low and side effects occur
Solution Approach 1:
The patent modifies the chemical structure of oxysterols by introducing specific functional groups and stereochemical configurations (e.g., 20(S)-hydroxycholesterol derivatives with specific double bond positions) to enhance bone targeting and bioavailability while maintaining bone resorption inhibition properties
Solution Approach 2:
The invention creates composite molecular structures by combining oxysterol core structures with various functional moieties (such as tetracycline derivatives, bisphosphonate groups, or peptide sequences) to achieve both bone targeting and therapeutic efficacy simultaneously
2Productivity
If recombinant human bone morphogenetic protein-2 (rhBMP-2) is used for spine fusion, then bone formation is stimulated, but safety concerns arise
Solution Approach 1:
The patent employs small molecule oxysterol derivatives that can be rapidly metabolized and eliminated from the body, avoiding the accumulation and long-term safety issues associated with protein-based therapies like rhBMP-2. The molecular weight and half-life are optimized for safe clinical use
Solution Approach 2:
The invention extracts and utilizes specific osteogenic activities from natural oxysterols (such as 20(S)-hydroxycholesterol) that are already present in biological systems, eliminating the need for foreign protein products and associated immunogenicity and safety concerns
3Productivity
If bone anabolic agents are developed to treat osteoporosis, then bone formation is enhanced, but systemic toxicity may occur
Solution Approach 1:
The patent introduces bone-targeting moieties (such as hydroxyapatite-binding groups, RGD peptides, or fosphenytoin derivatives) to the oxysterol structure, enabling the compound to accumulate specifically in bone tissue and minimize exposure to other organs and systems
Solution Approach 2:
The invention utilizes lipophilic oxysterol structures as intermediaries that can cross cell membranes and interact with intracellular osteogenic pathways (such as Wnt or Hedgehog signaling), providing effective bone stimulation while the molecule itself serves as the delivery vehicle that limits systemic distribution
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate robust osteogenic activity, inducing bone formation and spine fusion in animal models, offering a safer and more effective treatment option for osteoporosis and bone fractures by selectively targeting bone tissue and minimizing exposure to other tissues.
Implementation Method 1
A method of the present invention includes making and/or administering, such as locally and/or systemically, to a cell, an oxysterol-bone targeting agent compound, for example, so that a Hedgehog signaling pathway in the cell is stimulated
Data Source
AI summary
Compounds and compositions for the treatment of bone disorders are presented.